Captohexal is a medicine containing the active ingredient(s) captopril. On this page you will find out more about Captohexal, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: captopril
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Captohexal 25 mg film-coated tablet, 90
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
HYPERTENSION: Treatment of hypertension. In using Captopril Sanodz, consideration should be given to the risk of neutropenia/ agranulocytosis (see Warnings). Captopril Sanodz, is effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazide are approximately additive. MYOCARDIAL INFARCTION: To improve survival following myocardial infarction in clinicaly stable patients with left ventricular dysfuction, manifested as an ejection fraction <=40%, and to reduce the incidence of overt heart failure andsubsequent hospitalisations for congestive heart failure in these patients. The efficacy data for the use of Captopril Sanodz, following myocardial infarction are strongest for initiation of therapy beyond three days post-infarction. HEART FAILURE: Treatment of heart failure. In symptomatic patients it is recommended that Captopril Sanodz, be administered together with a diuretic. DIABETIC NEPHROPATHY: Treatmentt of diabetic nephropathy (proteinuria >= 500mg/day) in patients with Type I diabetes mellitus. In these patients Captopril Sanodz, reduces the progression of renal disease and reduces associated clinical sequelae (dialysis, renal transplantation and death).
Table of characteristics
Round tablets of a "cloverleaf" shape with facet and a crossed break mark on both sides, uniform white surface - diameter 8.0 - 8.2 mm.
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Tablet, film coated|
|Route of administration||Oral|
90 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Protect from Moisture|
|Life time||36 Months|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.